ACADIA Pharmaceuticals Appoints Stephanie Fagan as Senior Vice President, Corporate Affairs and Chief Communications Officer
December 18 2019 - 4:05PM
Business Wire
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that
Stephanie Fagan has been appointed to the newly created position of
Senior Vice President, Corporate Affairs and Chief Communications
Officer. Ms. Fagan will be responsible for all corporate
communications and serve as a member of the company’s Executive
Management Committee. She will report to Elena Ridloff, CFA,
Executive Vice President, Chief Financial Officer of ACADIA.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20191218005733/en/
Stephanie Fagan, Senior Vice President,
Corporate Affairs and Chief Communications Officer (Photo: Business
Wire)
“Stephanie brings extensive experience working with leading
healthcare companies and brands, and her commitment to patients,
customer and community engagement will strengthen the ACADIA
mission of improving the lives of people who struggle with unmet
needs in neurological disorders,” said Ms. Ridloff. “I’m delighted
to welcome Stephanie to ACADIA as her strong track record of
developing the communications function with high-performing teams
that engage multiple stakeholders will advance our business
strategies.”
“As ACADIA continues to expand its research, development and
commercial efforts, I look forward to working with the team and
engaging with the communities we serve to keep ACADIA at the
forefront of developing and delivering new therapies for patients
and their families with central nervous system disorders,” said Ms.
Fagan.
Ms. Fagan joins ACADIA from bluebird bio, Inc. where she was
Senior Vice President, Corporate Communications and built the first
communications function as the company transitioned from a clinical
stage to commercial stage company. Prior to bluebird, Ms. Fagan led
the corporate affairs functions at Alexion, Shire, and West Health
and has experience overseeing corporate, financial, product, and
internal communications, as well as corporate social
responsibility, patient advocacy, and government affairs. Over the
course of her career, Ms. Fagan has served in positions of
increasing influence and impact in the healthcare industry,
including roles at Johnson & Johnson, Allergan, Pharmacia, Inc.
(now Pfizer), and Boston Scientific Corporation.
Ms. Fagan earned a Master’s degree in Communications from Boston
University and a Bachelor’s degree in English from Wheaton College.
She is a member of the Arthur Page Society and The Seminar.
About ACADIA Pharmaceuticals ACADIA is a biopharmaceutical
company focused on the development and commercialization of
innovative medicines to address unmet medical needs in central
nervous system disorders. ACADIA has developed and commercialized
the first and only medicine approved for the treatment of
hallucinations and delusions associated with Parkinson’s disease
psychosis. ACADIA also has ongoing clinical development efforts in
additional areas with significant unmet need, including
dementia-related psychosis, major depressive disorder, the negative
symptoms of schizophrenia, and Rett syndrome. This press release
and further information about ACADIA can be found at:
www.acadia-pharm.com.
Forward-Looking Statements Statements in this press release that
are not strictly historical in nature are forward-looking
statements. These statements include but are not limited to
statements regarding the timing of future events. These statements
are only predictions based on current information and expectations
and involve a number of risks and uncertainties. Actual events or
results may differ materially from those projected in any of such
statements due to various factors, including the risks and
uncertainties inherent in drug development, approval and
commercialization, and the fact that past results of clinical
trials may not be indicative of future trial results. For a
discussion of these and other factors, please refer to ACADIA’s
annual report on Form 10-K for the year ended December 31, 2018 as
well as ACADIA’s subsequent filings with the Securities and
Exchange Commission. You are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date hereof. This caution is made under the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this
cautionary statement and ACADIA undertakes no obligation to revise
or update this press release to reflect events or circumstances
after the date hereof, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191218005733/en/
Media Contact: ACADIA Pharmaceuticals Inc. Stephanie Fagan (858)
212-0534 media@acadia-pharm.com
Investor Contact: ACADIA Pharmaceuticals Inc. Mark Johnson, CFA
(858) 261-2771 ir@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Apr 2023 to Apr 2024